Everyone in Phase 1a should be able to get the first of the two-shot COVID-19 vaccine series within three weeks of one being authorized by the FDA.
Author: Elizabeth Weise and Karen Weintraub, USA TODAY
USA TODAY vaccine panel: ‘Best news so far’ in COVID-19 fight, but logistical challenges remain
Expert panel pushes USA TODAY’s COVID-19 vaccine clock ahead on positive news, but logistical challenges loom in getting doses to Americans.
Johnson & Johnson pauses COVID-19 vaccine trial due to unexplained illness — the second US trial now on hold
The Phase 3 clinical trial was temporarily halted Monday because of an unexplained illness in one of the participants, Johnson & Johnson said.
Data, data and more data will make a coronavirus vaccine safe, USA TODAY’s vaccine panel says
USA TODAY’s expert panel sees steady progress toward a safe and effective COVID vaccine, urge public’s patience as trials proceed and data comes in.
Scientists outraged by White House appointees’ meddling with coronavirus information: ‘Outright egregious’
Scientists are “aghast” over news of White House meddling with public health reports that conflict with President Donald Trump’s coronavirus messaging.